reported that targeting CCR4 in Tregs by using anti-CCR4 can selectively deplete the Tregs and augment the response of tumor-specific CD8+ T cells, thereby improving the anti-tumor immune response (116). The gene discussed is CD8A; the disease is neoplasm.